Femasys, Inc. (FEMY)

Over the past six months, Femasys's stock price has been impacted by several events. FemBloc received full regulatory approval in Europe, the UK, and New Zealand. The company received FDA approval for its IDE supplement for the final phase of the FemBloc pivotal clinical trial in the U.S., with enrollment initiated in March 2026. FemaSeed received AMA CPT Editorial Panel approval for a new Category III CPT code, supporting its future reimbursement pathway. Femasys expanded its European commercial footprint with a strategic distribution partnership in Switzerland. The company completed a $12 million financing round and received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. Femasys announced financial results for the year ended December 31, 2025, reporting an accumulated deficit and substantial doubt about its ability to continue as a going concern.

Based on 5 years of historical data, Femasys Inc. exhibits distinct seasonal tendencies. September has historically been the strongest month for the stock, while April tends to be the weakest month. Overall, the company has an average annual return of 45.14% with a monthly win rate of 30.0%. The seasonal pattern has a consistency score of 71.9 (Very Good) based on 6 years of data.

Femasys, Inc. is a biomedical company focused on transforming women's healthcare through innovative, minimally invasive, and office-based therapeutic and diagnostic solutions. The company operates in the Healthcare sector, specifically in the Medical Equipment & Supplies and Surgical and Medical Instrument Manufacturing industries, addressing unmet needs in women's reproductive health, including fertility treatment and permanent birth control. Femasys's product portfolio includes FemaSeed Intratubal Insemination (ITI), FemVue, FemBloc, FemCerv, FemCath, FemChec, and FemSperm.

Femasys is a U.S. manufacturer with global regulatory approvals, actively commercializing its lead product innovations in the U.S. and key international markets. Its international reach includes Europe, with distribution partnerships for FemBloc in France, the Benelux region, and Switzerland, with initial commercial orders reported in Spain and France. FemBloc has also received regulatory approval in the UK and New Zealand.

Femasys has generally maintained a positive brand reputation, particularly among analysts, with a consensus rating of "Moderate Buy" or "Strong Buy". However, the company has disclosed substantial doubt about its ability to continue as a going concern and a need for significant additional funding, which introduces material financing and dilution risk. Femasys has received notices regarding continued listing requirements from Nasdaq, which can raise concerns about the company's stability. Slower-than-anticipated revenue ramp for FemBloc and high retail ownership can lead to increased stock volatility.

Femasys Inc. has a diverse ownership structure. Institutional investors hold a relatively low percentage of the stock, with a significant portion held by retail investors. Insiders hold a smaller percentage of the stock. Major institutional owners include Dauntless Investment Group, LLC, Vanguard Group Inc, and BlackRock, Inc. Notable individual insider owners include Edward R. Uzialko and Kathy Leesepsick.